Alpha DNA Investment Management LLC Purchases Shares of 10,663 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Alpha DNA Investment Management LLC bought a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,663 shares of the company's stock, valued at approximately $441,000.

Several other large investors have also added to or reduced their stakes in MIRM. Jones Financial Companies Lllp boosted its holdings in shares of Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after buying an additional 357 shares in the last quarter. R Squared Ltd bought a new position in Mirum Pharmaceuticals during the fourth quarter worth $69,000. AlphaQuest LLC grew its holdings in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after purchasing an additional 1,658 shares during the period. Summit Investment Advisors Inc. increased its stake in Mirum Pharmaceuticals by 8.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock valued at $172,000 after purchasing an additional 312 shares in the last quarter. Finally, Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $189,000.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 6,837 shares of the firm's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total value of $327,629.04. Following the completion of the transaction, the chief executive officer now directly owns 125,022 shares of the company's stock, valued at $5,991,054.24. This trade represents a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Peter Radovich sold 3,177 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $152,241.84. Following the sale, the chief operating officer now owns 29,588 shares in the company, valued at approximately $1,417,856.96. The trade was a 9.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 116,473 shares of company stock worth $5,249,134 over the last ninety days. 22.87% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on MIRM. HC Wainwright raised their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $58.20.

Mirum Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ:MIRM traded up $0.19 during mid-day trading on Wednesday, hitting $39.62. 524,598 shares of the company traded hands, compared to its average volume of 523,703. The stock has a 50-day moving average price of $44.76 and a two-hundred day moving average price of $43.97. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $54.23. The stock has a market cap of $1.96 billion, a P/E ratio of -19.61 and a beta of 1.00. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.